|Price Per Pill or Unit
|US Brand Name
|Sexaglitptin / Metformin
Kombiglyze XR 1000 mg contains two active ingredients; saxagliptin and metformin. It is used as an adjunct to diet and exercise to improve glucose levels in adults with type 2 diabetes when treatment with both saxagliptin and metformin is appropriate.
Generally, Kombiglyze XR should be administered once daily with the evening meal, with a gradual dose reduction to reduce the gastrointestinal effects of metformin. Be sure to consult your doctor before taking this medicine.
Kombiglyze XR has been contraindicated in patients with renal insufficiency, acute or chronic metabolic acidosis, hypersensitivity to metformin hydrochloride, history of serious hypersensitivity reaction to Kombiglyze extended-release tablet. Lactic acidosis is rare, but serious complications can occur due to metformin accumulation during the treatment. If lactic acidosis is suspected, the combination antidiabetic agent should be discontinued, and the patient should be hospitalised immediately. If pancreatitis (inflammation of the pancreas) is suspected, Kombiglyze XR should be discontinued, and appropriate management should be started.
Patients are advised to report symptoms of heart failure immediately. If heart failure develops, consider discontinuation of saxagliptin/metformin. The use of Kombiglyze XR is known to cause hypoglycaemia. Therefore, when insulin is used in combination with saxagliptin, a lower insulin dose may be required to reduce the risk of hypoglycaemia. The combination antidiabetic agent should be used only during pregnancy if needed. Because Saxagliptin/metformin are secreted in breast milk, caution should be taken when the antidiabetic agent is given to a nursing woman. The safety and effectiveness of this drug have not been established in children.
Nausea, vomiting, diarrhoea, headache, upper respiratory tract infection, hypersensitivity reactions, nasopharyngitis, infections, and acute pancreatitis. Hypoglycaemia (low blood sugar may be seen in people receiving insulin, such as sulphonylureas and in really impaired patients.